What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health‐care professionals? A systematic review

Author:

Tochel Claire1,Smith Michael1,Baldwin Helen12,Gustavsson Anders345,Ly Amanda1,Bexelius Christin5,Nelson Mia1,Bintener Christophe6,Fantoni Enrico7,Garre‐Olmo Josep8,Janssen Olin9,Jindra Christoph10,Jørgensen Isabella F.11,McKeown Alex2,Öztürk Buket12,Ponjoan Anna813,Potashman Michele H.14,Reed Catherine15,Roncancio‐Diaz Emilse7,Vos Stephanie9,Sudlow Cathie1,

Affiliation:

1. Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of EdinburghEdinburghUK

2. University of OxfordOxfordUK

3. Quantify ResearchStockholmSweden

4. Department of Neurobiology, Care Sciences & SocietyKarolinska InstituteStockholmSweden

5. F. Hoffmann‐La Roche Ltd.BaselSwitzerland

6. Alzheimer EuropeLuxembourg CityLuxembourg

7. GE HealthcareLife SciencesAmershamUK

8. Girona Biomedical Research Institute (IdibGI)GironaCataloniaSpain

9. Department of Psychiatry & NeuropsychologySchool for Mental Health & Neuroscience, Alzheimer Center Limburg, Maastricht UniversityMaastrichtthe Netherlands

10. Department of PsychiatryUniversity of OxfordOxfordUK

11. Novo Nordisk Foundation Center for Protein ResearchFaculty of Health & Medical SciencesUniversity of CopenhagenCopenhagenDenmark

12. Department of Clinical EpidemiologyAarhus University HospitalAarhusDenmark

13. Vascular Health Research Group (ISV‐Girona), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol)BarcelonaCataloniaSpain

14. BiogenCambridgeMAUSA

15. Eli Lilly and Company LimitedWindleshamUK

Funder

Innovative Medicines Initiative

European Federation of Pharmaceutical Industries and Associations

EFPIA

Publisher

Wiley

Subject

Psychiatry and Mental health,Clinical Neurology

Reference46 articles.

1. M.J.Prince.World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence incidence cost and trends.Alzheimer's Dis Int 2015;1–87

2. Defeating Alzheimer's disease and other dementias: a priority for European science and society

3. Alzheimer's disease

4. Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short‐term and Long‐term Clinical Trial Needs;Posner H.;Innov Clin Neurosci,2017

5. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts

Cited by 49 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3